294 related articles for article (PubMed ID: 38255825)
1. Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review.
Watanabe K; Seki N
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255825
[TBL] [Abstract][Full Text] [Related]
2. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
3. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
4. Targeting epigenetics using synthetic lethality in precision medicine.
Chen ES
Cell Mol Life Sci; 2018 Sep; 75(18):3381-3392. PubMed ID: 30003270
[TBL] [Abstract][Full Text] [Related]
5. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs.
Jackson RA; Chen ES
Pharmacol Ther; 2016 Jun; 162():69-85. PubMed ID: 26803999
[TBL] [Abstract][Full Text] [Related]
8. Targeting Chromatin Remodeling for Cancer Therapy.
Kaur J; Daoud A; Eblen ST
Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J; Zinda M; Riaz N; Durocher D; Zimmermann M; Koehler M; Reis-Filho JS; Powell SN
Cancer Discov; 2021 Jul; 11(7):1626-1635. PubMed ID: 33795234
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Hu Y; Guo M
Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
13. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
14. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
15. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
17. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis of Targeted Imaging and Therapy in Cancer Explorations with the Epigenetic Drugs.
Pandit P; Brahmkhatri V
Subcell Biochem; 2022; 100():503-521. PubMed ID: 36301504
[TBL] [Abstract][Full Text] [Related]
19. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
20. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
